Description of Invention: Available for licensing is a micro/nanoparticle oral vaccine delivery system that specifically targets the large intestine for vaccine deposition and in situ immune activation, with minimal perturbation in the upper part of the gastrointestinal (GI) tract.
Vaccine delivery to the large intestine has been experimentally demonstrated as an effective means for inducing mucosal immunity against infections transmitted through the recto-genital mucosal area such as sexually transmitted disease as well as fungal and parasitic infections. In this system, the vaccine components are encapsulated by nanometer-sized particles to allow optimal uptake once it reaches the lumen and makes contact with the intestinal mucosal surface. To protect from premature degradation and uptake in the upper GI, these particles are coated within micrometer-sized particles. This coating is designed with a pH- and time-dependent release profile that is optimized for vaccine uptake to occur within the large intestine. This particular feature may also make this technology a potential delivery system for recto-colon cancer therapies.
Vaccine delivery system for inducing mucosal immunity against a variety of infections transmitted through the recto-genital mucosal area
Potential delivery system for recto-colon cancer therapeutics
Potential delivery system for recto-colon immunotherapies or controlled drug release
Oral delivery provides a more practical and less invasive means of vaccine delivery to the large intestine compared to intrarectal or intracolorectal routes
Delivery system can be used against a variety of diseases transmitted through the recto-genital mucosa
Proof of concept has been demonstrated in vivo
In vitro data available
In vivo data available (animal)
Inventors: Qing Zhu (NCI) Jay A Berzofsky (NCI) James Talton (Nanotherapeutics, Inc.)
Collaborative Research Opportunity: The Center for Cancer Research, Vaccine Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Oral Delivery of a Vaccine to the Large Intestine to Induce Mucosal Immunity. Please contact John Hewes, Ph.D. at 301-435-3121 or firstname.lastname@example.org for more information.
For Licensing Information Please Contact: Jennifer Wong NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4633 Fax: 301-402-0220